AR109958A1 - Lactamas bicíclicas de piridona y sus métodos de uso - Google Patents
Lactamas bicíclicas de piridona y sus métodos de usoInfo
- Publication number
- AR109958A1 AR109958A1 ARP170102878A ARP170102878A AR109958A1 AR 109958 A1 AR109958 A1 AR 109958A1 AR P170102878 A ARP170102878 A AR P170102878A AR P170102878 A ARP170102878 A AR P170102878A AR 109958 A1 AR109958 A1 AR 109958A1
- Authority
- AR
- Argentina
- Prior art keywords
- group
- ring
- alkoxy
- cycloalkyl
- haloalkyl
- Prior art date
Links
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 7
- 125000000623 heterocyclic group Chemical group 0.000 abstract 6
- 229910052757 nitrogen Inorganic materials 0.000 abstract 6
- 125000001424 substituent group Chemical group 0.000 abstract 6
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 5
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 abstract 5
- 229910052760 oxygen Inorganic materials 0.000 abstract 5
- 229910052717 sulfur Chemical group 0.000 abstract 5
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 abstract 4
- 150000001875 compounds Chemical class 0.000 abstract 4
- 229910052736 halogen Inorganic materials 0.000 abstract 4
- 125000005843 halogen group Chemical group 0.000 abstract 4
- 229910052739 hydrogen Inorganic materials 0.000 abstract 4
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 4
- 125000004737 (C1-C6) haloalkoxy group Chemical group 0.000 abstract 3
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 abstract 3
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 3
- 239000001301 oxygen Chemical group 0.000 abstract 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 3
- 125000004001 thioalkyl group Chemical group 0.000 abstract 3
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 2
- 125000004765 (C1-C4) haloalkyl group Chemical group 0.000 abstract 2
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 abstract 2
- 125000004434 sulfur atom Chemical group 0.000 abstract 2
- 125000003831 tetrazolyl group Chemical group 0.000 abstract 2
- 125000004767 (C1-C4) haloalkoxy group Chemical group 0.000 abstract 1
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 abstract 1
- 125000006645 (C3-C4) cycloalkyl group Chemical group 0.000 abstract 1
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 abstract 1
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 abstract 1
- DBTDEFJAFBUGPP-UHFFFAOYSA-N Methanethial Chemical compound S=C DBTDEFJAFBUGPP-UHFFFAOYSA-N 0.000 abstract 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 abstract 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 abstract 1
- 229910052799 carbon Inorganic materials 0.000 abstract 1
- -1 cyano, phenyl Chemical group 0.000 abstract 1
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 1
- 235000019256 formaldehyde Nutrition 0.000 abstract 1
- 125000004005 formimidoyl group Chemical group [H]\N=C(/[H])* 0.000 abstract 1
- 125000001072 heteroaryl group Chemical group 0.000 abstract 1
- 125000005842 heteroatom Chemical group 0.000 abstract 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000011593 sulfur Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Epidemiology (AREA)
- Ophthalmology & Optometry (AREA)
- Vascular Medicine (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
La presente solicitud proporciona compuestos, composiciones farmacéuticas que incluyen los compuestos y los métodos para usar los compuestos. Reivindicación 1: Un compuesto de fórmula (1), o una sal farmacéuticamente aceptable del mismo, en donde: R¹ se selecciona entre el grupo que consiste en H, alquilo C₁₋₄ y haloalquilo C₁₋₄; el anillo A es tetrazolilo o un heteroarilo de 5 ó 6 miembros con entre 1 y 3 heteroátomos seleccionados entre el grupo que consiste en nitrógeno, oxígeno y azufre; en donde el anillo A es opcionalmente sustituido por 1 ó 2 sustituyentes seleccionados entre el grupo que consiste en halógeno, alquilo C₁₋₄, cicloalquilo C₃₋₄, haloalquilo C₁₋₄, alcoxi C₁₋₄, haloalcoxi C₁₋₄ y ciano; y en donde, si se sustituye un átomo de nitrógeno en el anillo A, el sustituyente no es halógeno, ciano, o un alcoxi C₁₋₆, haloalcoxi C₁₋₆ o tioalquilo C₁₋₆ con un átomo de oxígeno o de azufre directamente unido al átomo de nitrógeno; el anillo B se selecciona entre el grupo que consiste en fenilo, heteroarilo de 5 ó 6 miembros, cicloalquilo de 3 a 7 miembros, y heterociclilo de 4 a 7 miembros; en donde el anillo B es opcionalmente sustituido por: (a) de 1 a 4 sustituyentes seleccionados entre el grupo que consiste en halógeno, alquilo C₁₋₆, haloalquilo C₁₋₆, cicloalquilo C₃₋₆, alcoxi C₁₋₆, haloalcoxi C₁₋₆, tioalquilo C₁₋₆, ciano, fenilo, bencilo, CH₂-(cicloalquilo C₃₋₆), y CH₂CH₂-(cicloalquilo C₃₋₆); en donde, si se sustituye un átomo de nitrógeno en el anillo C, el sustituyente no es halógeno, ciano, o un alcoxi C₁₋₆, haloalcoxi C₁₋₆ o tioalquilo C₁₋₆ con un átomo de oxígeno o de azufre directamente unido al átomo de nitrógeno; (b) de 1 a 2 sustituyentes seleccionados entre el grupo que consiste en alquilo C₁₋₆, haloalquilo C₁₋₆, alcoxi C₁₋₆, haloalcoxi C₁₋₆, CH₂-(heterociclilo de 4 a 6 miembros), CH₂CH₂-(heterociclilo de 4 a 6 miembros), y heteroarilo insustituido de 5 ó 6 miembros; o (c) dos sustituyentes adyacentes que juntos, forman fenilo, heteroarilo de 5 ó 6 miembros, heterociclilo de 4 a 6 miembros o cicloalquilo C₄₋₆; L se selecciona entre el grupo que consiste en un enlace, O, S, NH, NCH₃, (CH₂)ₘ, CH(CH₃), C(CH₃)₂, CF₂, CH₂O, CH₂S, CH(OH), CH₂NH, y CH₂N(CH₃), o L está ausente de manera tal que el anillo A y el anillo B se fusionen; X se selecciona entre el grupo que consiste en O, S, SO, SO₂, CH₂, C(CH₃)₂, CF₂ y CHCF₃; cada uno de Z¹ a Z⁴ se selecciona, en forma independiente, entre el grupo que consiste en CR², NR³ y C=O; Z⁵ es C o N; en donde solo uno de Z¹ a Z⁴ es C=O; y: (i) si Z¹ es C=O y Z⁵ es N, entonces Z², Z³, Z⁴ son, cada uno CR² y X es CH₂; (ii) si Z¹ es C=O y Z² es N, entonces Z³ y Z⁴ son, cada uno CR² y Z⁵ es C; (iii) si Z² es C=O y Z¹ es NR³, entonces Z³ y Z⁴ son, cada uno CR² y Z⁵ es C; (iv) si Z² es C=O y Z³ es NR³, entonces Z¹ y Z⁴ son, cada uno CR² y Z⁵ es C; (v) si Z³ es C=O y Z² es NR³, entonces Z¹ y Z⁴ son, cada uno CR² y Z⁵ es C; (vi) si Z³ es C=O y Z⁴ es NR³, entonces Z¹ y Z² son, cada uno CR² y Z⁵ es C; (vii) si Z⁴ es C=O y Z³ es NR³, entonces Z¹ y Z² son, cada uno CR² y Z⁵ es C; n es 1 ó 2; R² se selecciona entre el grupo que consiste en H, F, alquilo C₁₋₆, alcoxi C₁₋₆, y haloalquilo C₁₋₆; R³ se selecciona entre el grupo que consiste en H, alquilo C₁₋₆, haloalquilo C₁₋₆, alcoxi C₁₋₆, cicloalquilo C₃₋₆,-C(R⁴)₂-cicloalquilo C₃₋₆, heterociclilo de 4 a 6 miembros, y -C(R⁴)₂-(heterociclilo de 4 a 6 miembros); y cada R⁴ se selecciona, en forma independiente, entre el grupo que consiste en H, F, alquilo C₁₋₆, alcoxi C₁₋₆, y haloalquilo C₁₋₆; siempre que, si el anillo B es tetrazolilo, L se seleccione entre el grupo que consiste en CH₂, CH(CH₃), C(CH₃)₂, CF₂; y el anillo C es fenilo.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662409214P | 2016-10-17 | 2016-10-17 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR109958A1 true AR109958A1 (es) | 2019-02-06 |
Family
ID=60191355
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP170102878A AR109958A1 (es) | 2016-10-17 | 2017-10-17 | Lactamas bicíclicas de piridona y sus métodos de uso |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US10947226B2 (es) |
| EP (1) | EP3526219B1 (es) |
| JP (1) | JP7349359B2 (es) |
| CN (1) | CN109843886B (es) |
| AR (1) | AR109958A1 (es) |
| TW (1) | TW201821424A (es) |
| WO (1) | WO2018073193A1 (es) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX380753B (es) | 2015-07-02 | 2025-04-01 | Hoffmann La Roche | Lactamas bicíclicas y métodos de uso de las mismas. |
| CA3002542C (en) | 2015-10-23 | 2023-11-28 | Takeda Pharmaceutical Company Limited | Substituted azepin heterocyclic derivatives and compositions thereof useful as rip1 kinase inhibitor |
| WO2017109724A1 (en) | 2015-12-21 | 2017-06-29 | Glaxosmithkline Intellectual Property Development Limited | Heterocyclic amides as kinase inhibitors |
| EP3526219B1 (en) * | 2016-10-17 | 2021-12-15 | F. Hoffmann-La Roche AG | Bicyclic pyridone lactams and methods of use thereof |
| US11072607B2 (en) * | 2016-12-16 | 2021-07-27 | Genentech, Inc. | Inhibitors of RIP1 kinase and methods of use thereof |
| EP3781571B1 (en) | 2018-04-20 | 2024-01-17 | F. Hoffmann-La Roche AG | N-[4-oxo-2,3-dihydro-pyrido[3,2-b][1,4]oxazepin-3-yl]-5,6-dihydro-4h-pyrrolo[1,2-b]pyrazole-2-carboxamide derivatives and related compounds as rip1 kinase inhibitors for treating e.g. irritable bowel syndrome (ibs) |
| BR112020022423A2 (pt) | 2018-05-03 | 2021-02-02 | Rigel Pharmaceuticals, Inc. | composto, composição farmacêutica, método, método para tratar uma doença em um indivíduo e método para fabricar o composto |
| RS64736B1 (sr) | 2018-05-03 | 2023-11-30 | Rigel Pharmaceuticals Inc | Jedinjenja inhibitori rip1 i postupci za njihovo dobijanje i upotrebu |
| US20210292340A1 (en) * | 2018-06-26 | 2021-09-23 | Shanghai Institute Of Organic Chemistry, Chinese Academy Of Sciences | Cell necrosis inhibitor, preparation method therefor and use thereof |
| EP4025568B1 (en) | 2019-09-06 | 2025-05-14 | Rigel Pharmaceuticals, Inc. | Rip1 inhibitory compounds and methods for making and using the same |
| US11564930B2 (en) | 2019-09-06 | 2023-01-31 | Rigel Pharmaceuticals, Inc. | RIP1 inhibitory compounds and methods for making and using the same |
| US11718612B2 (en) | 2019-09-06 | 2023-08-08 | Board Of Regents, The University Of Texas System | Inhibitors of receptor interacting protein kinase I for the treatment of disease |
| IL291665B2 (en) | 2019-09-27 | 2025-07-01 | Univ Texas | Inhibitors of receptor interacting protein kinase i for the treatment of disease |
| IL292536A (en) | 2019-11-07 | 2022-06-01 | Rigel Pharmaceuticals Inc | Heterocyclic compounds inhibit rip1 |
| AU2020391425A1 (en) * | 2019-11-26 | 2022-06-16 | Board Of Regents, The University Of Texas System | Inhibitors of Receptor Interacting Protein Kinase 1 for the treatment of disease |
| BR112022017099A2 (pt) * | 2020-02-28 | 2022-11-16 | Univ Texas | Composto, composição farmacêutica, método para inibição de ripk1, método para tratamento de uma doença mediada por ripk1 e método para tratamento de lesão no snc |
| AR121717A1 (es) | 2020-04-02 | 2022-06-29 | Rigel Pharmaceuticals Inc | Inhibidores de rip1k |
| TWI840311B (zh) | 2020-07-01 | 2024-04-21 | 美商雷傑製藥公司 | Rip1k抑制劑 |
| AR125587A1 (es) | 2021-03-11 | 2023-08-02 | Rigel Pharmaceuticals Inc | Inhibidores heterocíclicos de la quinasa de rip1 |
| CN115246796A (zh) * | 2021-04-27 | 2022-10-28 | 中国科学院上海有机化学研究所 | 一种抑制细胞程序性死亡的化合物及其制备方法 |
| WO2023020486A1 (zh) * | 2021-08-17 | 2023-02-23 | 广州市恒诺康医药科技有限公司 | Rip1激酶抑制剂类化合物及其组合物和用途 |
Family Cites Families (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US4485045A (en) | 1981-07-06 | 1984-11-27 | Research Corporation | Synthetic phosphatidyl cholines useful in forming liposomes |
| EP0102324A3 (de) | 1982-07-29 | 1984-11-07 | Ciba-Geigy Ag | Lipide und Tenside in wässriger Phase |
| US4544545A (en) | 1983-06-20 | 1985-10-01 | Trustees University Of Massachusetts | Liposomes containing modified cholesterol for organ targeting |
| HUT35524A (en) | 1983-08-02 | 1985-07-29 | Hoechst Ag | Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance |
| US5004697A (en) | 1987-08-17 | 1991-04-02 | Univ. Of Ca | Cationized antibodies for delivery through the blood-brain barrier |
| US5268164A (en) | 1990-04-23 | 1993-12-07 | Alkermes, Inc. | Increasing blood-brain barrier permeability with permeabilizer peptides |
| US5112596A (en) | 1990-04-23 | 1992-05-12 | Alkermes, Inc. | Method for increasing blood-brain barrier permeability by administering a bradykinin agonist of blood-brain barrier permeability |
| US5206234A (en) | 1990-10-22 | 1993-04-27 | Merck & Co., Inc. | Benzolactam analogs as antagonists of cck |
| EP0652775B1 (en) | 1992-07-27 | 2000-04-19 | THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by the SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES | Targeting of liposomes to the blood-brain barrier |
| WO1998024804A2 (en) | 1996-12-06 | 1998-06-11 | Vertex Pharmaceuticals Incorporated | INHIBITORS OF INTERLEUKIN-1β CONVERTING ENZYME |
| US6514221B2 (en) | 2000-07-27 | 2003-02-04 | Brigham And Women's Hospital, Inc. | Blood-brain barrier opening |
| AU2001286930A1 (en) | 2000-08-30 | 2002-03-13 | The Board Of Trustees Of The Leland Stanford Junior University | Glucocorticoid blocking agents for increasing blood-brain barrier permeability |
| GB0021831D0 (en) | 2000-09-06 | 2000-10-18 | Astrazeneca Ab | Chemical compounds |
| US7034036B2 (en) | 2000-10-30 | 2006-04-25 | Pain Therapeutics, Inc. | Inhibitors of ABC drug transporters at the blood-brain barrier |
| DE10121982B4 (de) | 2001-05-05 | 2008-01-24 | Lts Lohmann Therapie-Systeme Ag | Nanopartikel aus Protein mit gekoppeltem Apolipoprotein E zur Überwindung der Blut-Hirn-Schranke und Verfahren zu ihrer Herstellung |
| DE60234057D1 (de) | 2001-07-25 | 2009-11-26 | Raptor Pharmaceutical Inc | Zusammensetzungen und verfahren zur modulation des transports durch die blut-hirn-schranke |
| AU2002359476A1 (en) | 2001-11-26 | 2003-06-10 | Exelixis, Inc. | MAP4Ks AS MODIFIERS OF BRANCHING MORPHOGENESIS AND METHODS OF USE |
| US20030162695A1 (en) | 2002-02-27 | 2003-08-28 | Schatzberg Alan F. | Glucocorticoid blocking agents for increasing blood-brain barrier permeability |
| US7057046B2 (en) | 2002-05-20 | 2006-06-06 | Bristol-Myers Squibb Company | Lactam glycogen phosphorylase inhibitors and method of use |
| WO2004038372A2 (en) | 2002-10-23 | 2004-05-06 | Exelixis, Inc. | Cdkl1 as modifier of branching morphogenesis and methods of use |
| US7220833B2 (en) | 2002-12-03 | 2007-05-22 | Thomas Nelson | Artificial low-density lipoprotein carriers for transport of substances across the blood-brain barrier |
| JP2007505142A (ja) | 2003-09-10 | 2007-03-08 | セダーズ−シナイ メディカル センター | 血液脳関門を通過する薬剤のカリウムチャネル媒介性送達 |
| US7390798B2 (en) | 2004-09-13 | 2008-06-24 | Merck & Co., Inc. | Carboxamide spirolactam CGRP receptor antagonists |
| RU2281947C1 (ru) | 2005-07-05 | 2006-08-20 | Общество С Ограниченной Ответственностью "Исследовательский Институт Химического Разнообразия" | Аннелированные карбамоилазагетероциклы, фокусированная библиотека, фармацевтическая композиция и способ получения |
| CA2635615A1 (en) | 2005-12-30 | 2007-07-12 | Merck Patent Gesellschaft Mit Beschraenkter Haftung | Anti-il-6 antibodies preventing the binding of il-6 complexed with il-6ralpha to gp130 |
| ES2343481T3 (es) | 2006-07-21 | 2010-08-02 | Vertex Pharmaceuticals, Inc. | Antagonistas del receptor cgrp. |
| CN102056927B (zh) | 2008-05-13 | 2014-06-25 | Irm责任有限公司 | 作为激酶抑制剂的稠合含氮杂环及其组合物 |
| TW201837023A (zh) | 2011-07-01 | 2018-10-16 | 美商基利科學股份有限公司 | 作為離子通道調節劑之稠合雜環化合物 |
| CA2888805C (en) | 2011-10-21 | 2020-07-14 | Massachusetts Eye And Ear Infirmary | Methods and compositions for promoting axon regeneration and nerve function |
| CN104507913B (zh) | 2012-07-13 | 2017-07-28 | 霍夫曼-拉罗奇有限公司 | 抗增殖的苯并[b]氮杂*‑2‑酮 |
| JP6266617B2 (ja) | 2012-08-09 | 2018-01-24 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | 置換ヘテロアゼピノン |
| TWI638815B (zh) | 2013-02-15 | 2018-10-21 | 英商葛蘭素史克智慧財產發展有限公司 | 作為激酶抑制劑之雜環醯胺類（一） |
| EP2968276A4 (en) | 2013-03-15 | 2017-02-15 | President and Fellows of Harvard College | Hybrid necroptosis inhibitors |
| EP2986317A4 (en) | 2013-04-15 | 2016-10-05 | Yeda Res & Dev | INHIBITION OF RIP KINASES FOR THE TREATMENT OF LYSOSOMAL STORAGE DISEASES |
| US20170266199A1 (en) | 2014-08-21 | 2017-09-21 | Glaxosmithkline Intellectual Property Development Limited | Heterocyclic amides as rip1 kinase inhibitors as medicaments |
| MX380753B (es) * | 2015-07-02 | 2025-04-01 | Hoffmann La Roche | Lactamas bicíclicas y métodos de uso de las mismas. |
| CN112047960B (zh) | 2015-07-02 | 2024-08-02 | 豪夫迈·罗氏有限公司 | 苯并氧氮杂䓬噁唑烷酮化合物及其使用方法 |
| US10875876B2 (en) | 2015-07-02 | 2020-12-29 | Janssen Sciences Ireland Uc | Cyclized sulfamoylarylamide derivatives and the use thereof as medicaments for the treatment of hepatitis B |
| KR20170004814A (ko) | 2015-07-02 | 2017-01-11 | 주식회사 녹십자 | 헌터증후군 치료제 |
| SMT202200220T1 (it) | 2015-07-02 | 2022-07-21 | Janssen Sciences Ireland Unlimited Co | Composti antibatterici |
| US10709692B2 (en) | 2015-12-04 | 2020-07-14 | Denali Therapeutics Inc. | Isoxazolidine derived inhibitors of receptor interacting protein kinase 1 (RIPK1) |
| AU2016370779B2 (en) | 2015-12-17 | 2019-07-25 | Astex Therapeutics Limited | Quinoline-3-carboxamides as H-PGDS inhibitors |
| WO2017109724A1 (en) | 2015-12-21 | 2017-06-29 | Glaxosmithkline Intellectual Property Development Limited | Heterocyclic amides as kinase inhibitors |
| BR112018012647A2 (pt) | 2015-12-23 | 2018-12-04 | Harvard College | composto, método para tratamento de um hospedeiro, e, uso de um composto. |
| KR102808827B1 (ko) | 2016-02-05 | 2025-05-19 | 데날리 테라퓨틱스 인크. | 수용체-상호작용 단백질 키나제 1의 억제제 |
| EP3526219B1 (en) * | 2016-10-17 | 2021-12-15 | F. Hoffmann-La Roche AG | Bicyclic pyridone lactams and methods of use thereof |
| US11072607B2 (en) | 2016-12-16 | 2021-07-27 | Genentech, Inc. | Inhibitors of RIP1 kinase and methods of use thereof |
| EP3781571B1 (en) | 2018-04-20 | 2024-01-17 | F. Hoffmann-La Roche AG | N-[4-oxo-2,3-dihydro-pyrido[3,2-b][1,4]oxazepin-3-yl]-5,6-dihydro-4h-pyrrolo[1,2-b]pyrazole-2-carboxamide derivatives and related compounds as rip1 kinase inhibitors for treating e.g. irritable bowel syndrome (ibs) |
| EP4025568B1 (en) | 2019-09-06 | 2025-05-14 | Rigel Pharmaceuticals, Inc. | Rip1 inhibitory compounds and methods for making and using the same |
| AR121717A1 (es) | 2020-04-02 | 2022-06-29 | Rigel Pharmaceuticals Inc | Inhibidores de rip1k |
-
2017
- 2017-10-16 EP EP17791625.1A patent/EP3526219B1/en active Active
- 2017-10-16 JP JP2019520524A patent/JP7349359B2/ja active Active
- 2017-10-16 WO PCT/EP2017/076385 patent/WO2018073193A1/en not_active Ceased
- 2017-10-16 CN CN201780063771.7A patent/CN109843886B/zh active Active
- 2017-10-17 AR ARP170102878A patent/AR109958A1/es unknown
- 2017-10-17 TW TW106135521A patent/TW201821424A/zh unknown
-
2019
- 2019-04-16 US US16/385,353 patent/US10947226B2/en active Active
-
2021
- 2021-02-04 US US17/168,158 patent/US12139482B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US20190241565A1 (en) | 2019-08-08 |
| US10947226B2 (en) | 2021-03-16 |
| TW201821424A (zh) | 2018-06-16 |
| WO2018073193A1 (en) | 2018-04-26 |
| JP7349359B2 (ja) | 2023-09-22 |
| US12139482B2 (en) | 2024-11-12 |
| US20210163475A1 (en) | 2021-06-03 |
| JP2019530726A (ja) | 2019-10-24 |
| EP3526219B1 (en) | 2021-12-15 |
| CN109843886B (zh) | 2022-04-19 |
| CN109843886A (zh) | 2019-06-04 |
| EP3526219A1 (en) | 2019-08-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR109958A1 (es) | Lactamas bicíclicas de piridona y sus métodos de uso | |
| PE20221336A1 (es) | Compuestos triciclicos sustituidos | |
| AR120896A1 (es) | COMPUESTO DE PIRIDAZINIL-TIAZOLCARBOXAMIDA COMO INHIBIDORES DE DGKz | |
| AR099498A1 (es) | Compuestos de triazina y su uso farmacéutico | |
| AR108710A1 (es) | Compuestos modulares de fxr (nr1h4) | |
| AR109438A1 (es) | Compuestos tricíclicos fusionados de piridazinona útiles para tratar infecciones de orthomyxovirus | |
| ES2393824T3 (es) | Derivados de piridin-2-il-amino-1,2,4-tiadiazol como activadores de glucoquinasa para el tratamiento de diabetes mellitus | |
| AR091176A1 (es) | Pirrodilina-2-carboxamidas sustituidas | |
| AR105845A1 (es) | Compuestos de heteroarilo bicíclicos fusionados como moduladores de la función irak4 | |
| AR104716A1 (es) | Agonistas de triazol del receptor apj | |
| AR110282A1 (es) | Compuestos de amida bicíclica y uso de éstos en el tratamiento de enfermedades mediadas por rip1 | |
| AR080314A1 (es) | Derivado de 1,3,4,8-tetrahidro-2h-pirido (1,2-a) pirazina y su uso como inhibidor de la hiv integrasa | |
| AR103833A1 (es) | Compuestos bicíclicos de sulfonamida cetona | |
| AR088449A1 (es) | Benzilindazoles sustituidos | |
| AR088829A1 (es) | DERIVADOS DE CICLOHEXILAMINA QUE TIENEN ACTIVIDAD COMO AGONISTAS ADRENERGICOS b2 Y COMO ANTAGONISTAS MUSCARINICOS M3 | |
| AR085615A1 (es) | Derivados de fluoropiridinona utiles como agentes antibacterianos y composiciones farmaceuticas que los contienen | |
| AR088828A1 (es) | DERIVADOS DE CICLOHEXILAMINA QUE TIENEN ACTIVIDAD COMO AGONISTAS ADRENERGICOS b2 Y COMO ANTAGONISTAS MUSCARINICOS M3 | |
| AR092008A1 (es) | Composiciones que comprenden benzodiazepinas de accion rapida, uso y metodo de preparacion | |
| AR103232A1 (es) | ANTAGONISTAS DE TGFbR | |
| EA201600403A1 (ru) | N-ацилиминогетероциклические соединения | |
| AR092288A1 (es) | Ligandos del receptor ep1 | |
| AR069813A1 (es) | Derivados de 2- amino-pirimidina, una composicion farmaceutica, un metodo de preparacion del compuesto y uso del mismo para preparar un medicamento | |
| CO6260066A2 (es) | Derivados de azetidina y su uso como antagonistas de prostaglandina e2 | |
| AR113811A1 (es) | Sulfonas y sulfóxidos bicíclicos y métodos de uso de los mismos | |
| AR109651A1 (es) | Compuestos de piridina y pirazina como inhibidores de ripk2 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |